Friday, 6 November 2026
RACGP member survey opens, Health technology’s dystopian fears, Nurses seek team care funding
- 01
RACGP opens 2026 member survey on advocacy and services
The RACGP has opened its 2026 Member Engagement Survey to members until 29 November. The survey seeks feedback on the college’s advocacy, member services and future priorities. The RACGP said responses would inform support for GPs in training and advocacy on remuneration, workforce and scope-of-practice issues, while helping create opportunities for members to connect. Members will receive a personalised survey link by email, and participants will enter a draw for one year of complimentary RACGP membership fees.
via RACGP newsGP
- 02
Dystopian fiction reflects fears of health technology and its absence
Public anxiety about AI and reliance on health technology reflects fears both of technological control and of living without modern care, according to commentary by former digital health policy executive Simon Tatz. The commentary identifies two recurring dystopian scenarios: medicines, machines and medical systems become tools of coercion, or healthcare and digital infrastructure disappear entirely. It draws on works including The Handmaid’s Tale, Gattaca, The Road and Station Eleven to explore reproductive control, genetic discrimination, organ harvesting and the consequences of collapsed health services. Tatz argues that these stories expose human frailty and question whether healthcare can continue when social institutions, communities and relationships break down.
- 03
Nursing peaks seek dedicated funding for multidisciplinary team work
Nine nursing peak bodies have called for dedicated Commonwealth funding for multidisciplinary team activities performed outside direct patient consultations. Their joint position statement builds on the 2024 scope of practice review and seeks remuneration for care coordination, cross-setting collaboration and referral activities. Australian College of Nursing CEO Adjunct Professor Kathryn Zeitz said dedicated funding for case conferences, shared care planning and discharge or transition management would support the financial viability of nurse- and midwife-led initiatives. She also argued that funding reforms should recognise care models outside traditional GP clinics and allow funding to follow the patient rather than the profession. The coalition called for modernised funding, person-centred governance, advanced practice pathways, flexible solutions and connected digital health systems.
- 04
Rasonque records $198 million in first five weeks
After FDA documents showed uneven Rasonque responses across KRAS mutations, Revolution Medicines reported $198 million in third-quarter revenue from the pancreatic cancer drug’s first five weeks on the US market. More than 5,000 patients received treatment through 30 September, with 2,700 prescribers split between academic settings and community practices. A TD Cowen analyst described it as the best oncology drug launch in history, while the company said health plans covering more than 90% of patients were reimbursing claims. Revolution cautioned that early-access patients boosted initial sales and that five weeks of commercial activity was too short to establish the launch trajectory.
via BioPharma Dive
- 05
Early trispecific antibody data show activity in multiple myeloma
Early trials of trispecific antibodies that bind three targets showed high response rates in multiple myeloma. In a mid-stage trial, all 20 evaluable, newly diagnosed transplant-eligible patients achieved minimal residual disease negativity after three cycles of J&J’s ramantamig with Darzalex and Revlimid. AbbVie’s ABBV-2001 produced responses in 75% to 85% of participants with relapsed or refractory disease, while 83% to 88% of those achieving a complete response were also MRD-negative. Phase 1 data showed a 77% response rate at the selected Phase 2 dose for Innovent’s IBI3003, while Shanghai Xianxiang’s SIM0500 achieved an overall response rate as high as 86% at the highest tested doses.
via BioPharma Dive
- 06
T-Therapeutics raises $133 million for bispecific drug development
T-Therapeutics raised $133 million in Series B financing to support development of cancer and autoimmune disease therapies. Its lead bispecific antibody, TTX-008, targets an unspecified pan-tumour driver, while TTX-018 is designed for autoimmune conditions; neither has entered human testing. The company said the funding would help generate proof-of-concept data for both candidates, but disclosed few details about their targets or development plans. T-Therapeutics claims its technology can produce highly specific, fully human T-cell receptors directed at previously undruggable intracellular targets. The financing comes amid strong industry interest in T-cell engagers for solid tumours and immune diseases.
via BioPharma Dive
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.